|
|
 |
|
Viewing report
|
|
|
|
Bipolar Disorder: Can Competitive Advantage Be Established in a Challenging Market
Decision Resources, Inc., March 2007, Pages: 21
A poorly understood, complex disease that involves a number of neurotransmitters, bipolar disorder presents several challenges for pharmaceutical companies seeking to develop new treatments. While lithium and several antiepileptic and antipsychotic agents are currently used to treat either manic or mixed episodes of BPD, only Eli Lilly’s Symbyax and AstraZeneca’s Seroquel have received FDA approval for treatment of bipolar depression. The numerous unmet therapeutic needs resulting from the incomplete understanding of BPD create significant opportunities within the competitive BPD market.
Get the Answers You Need to Shape Your Strategy
Bipolar disorder represents a market with significant opportunity, but few drug companies are actively developing new agents. What obstacles are currently deterring companies from entering the BPD market? What challenges need to be addressed, and what therapeutic needs remain unmet?
The treatment of depression associated with BPD has not been as extensively studied as the treatment of either unipolar depression or bipolar mania. What strategies does treatment of bipolar depression rely upon? Which classes of antidepressants appear to be the most effective for treating bipolar depression?
Several agents have received specific approval for treating BPD; other agents are commonly used off-label. Which agents are most frequently used as off-label treatments for BPD? What competitive advantages, if any, does FDA approval provide? Which companies are specifically pursuing FDA approval for their BPD agents?
Scope
- BPD background: Symptoms, pathophysiology, and etiology.
- Treatment options: Current therapies for the four common types of episodes associated with bipolar I disorder and bipolar II disorder.
- Market dynamics: Sales growth statistics for BPD-approved agents versus non-BPD-approved agents; sales and prescriptions of antipsychotics and antiepileptics in the United States.
- Emerging therapies: Antipsychotics and sodium- and calcium-channel blockers currently in development, along with novel approaches.
- Market outlook: Limitations of current BPD agents; challenges still remaining; and the likelihood that any one agent will dominate the BPD market.
Customers who bought this item also bought
Pipeline Insight: Bipolar Disorder - New Treatments for Bipolar Depression Set to Drive Near-term Growth
Glycogen synthase kinase 3 inhibitors: Proof of concept and therapeutic opportunities for the treatment of diabetes, Alzheimers disease, stroke and bipolar disorder
Treatment Algorithms: Major Depressive Disorder, 4th Edition - Gaining Competitive Advantage in a Mature Environment
CNS Therapy US Market Survey: Analysis and Forecasts - Technology, Sales and Company Profiles
CNS Therapy Worldwide Market Survey: Analysis and Forecasts - Technology, Sales and Company Profiles
Stakeholder Insight: Bipolar Disorders - Zyprexa Sets the Mood for Revenue Growth
Drugs of Tomorrow: Antipsychotics - Gaining Competitive Advantage From a Limited Research Base
Strategic Perspectives 2001: Panic Disorder - Opportunities For Antidepressant Expansion
|
|
|
|
